<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04364347</url>
  </required_header>
  <id_info>
    <org_study_id>CIRCADIAN</org_study_id>
    <nct_id>NCT04364347</nct_id>
  </id_info>
  <brief_title>Chemotherapy-induced Circadian Rhythm Disruption</brief_title>
  <official_title>Chemotherapy-induced Circadian Rhythm Disruption: Investigation Using Biomarker</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Foundation of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate chemotherapy-induced circadian rhythm disruption
      through biomarkers, and the relationship between chemotherapy-induced circadian rhythm
      disruptions and side effects of chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasma melatonin, cortisol levels before, after and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), T2(9 months after chemotherapy termination)</time_frame>
    <description>12 times in 24 hours at 2 hour intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in core body temperature before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), T2(9 months after chemotherapy termination)</time_frame>
    <description>for 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in PBMC(Peripheral Blood Mononuclear Cell) mRNA levels before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), T2(9 months after chemotherapy termination)</time_frame>
    <description>12 times in 24 hours at 2 hour intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in plasma protein levels before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>6 times in 24 hours at 4 hour intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DNA</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy)</time_frame>
    <description>First one only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in MAT scores before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>MAT(Multinational Association of Supportive Care in Cancer Antiemesis tool) / Evaluating acute/delayed nausea and vomiting in patients treated with chemotherapy / High scores mean severe nausea and vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in EORTC-QLQ CIPN20 scores before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>EORTC-QLQ CIPN20(European Organization for Research and Treatment of Cancer Quality of Life Chemotherapy-induced Peripheral Neuropathy) / Peripheral neuropathy evaluation (It consists of 9 questions of sensory nerve area, 8 questions of motor nerve area and 3 questions of autonomic nerve area.) / High scores mean severe peripheral neuropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hot flush symptoms before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>Assessment of the number and severity of hot flashes (mild, moderate, severe) for 1 week / High scores mean severe hot flush</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MEQ scores before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>MEQ(Morningness-Eveningness Questionnaire) / Individual circadian rhythm evaluation / Consists of 19 questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MCTQ scores before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>MCTQ(Munich Chronotype Questionnaire) / Assessment of circadian rhythm discrepancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FACT-B scores before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>FACT-B(Functional Assessment of Cancer Therapy-Breast) / Measuring the quality of life of breast cancer patients / Self-report questionnaire of 44 items / High score means low quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MDASI scores before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>MDASI(M. D. Anderson Symptom Inventory) / Cancer-related physical symptoms evaluation / High score means severe physical symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HADS scores before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>HADS(Hospital anxiety and depression scale) / Depression, anxiety evaluation of patients with physical illness / Self-report questionnaire with 14 items / High score means severe depression and anxiety symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MSPSS scores before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>MSPSS(Multidimensional Scale of Perceived Social Support) / Social support assessment / Self-report questionnaire of 12 items / High score means high social support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PSQI scores before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>PSQI(Pittsburgh Sleep Quality Index) / Evaluate sleep quality in the past month / High scores mean severe sleep disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Actigraphy pattern before chemotherapy, after chemotherapy, and 9 months after chemotherapy</measure>
    <time_frame>T0(2 weeks before the start of chemotherapy), T1(2 weeks after chemotherapy termination), C3(Just before the third chemotherapy), C7(Just before the 7th chemotherapy), T2(9 months after chemotherapy termination)</time_frame>
    <description>Activity measurement / Records information such as weekly activity, time to go to bed, sleep incubation period, number of awakenings during sleep, wake-up time, and brightness of ambient light</description>
  </secondary_outcome>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Breast Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        University (Tertiary) hospital, oncology clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Those who have undergone breast cancer surgery and are waiting for chemotherapy

          2. premenopausal women

          3. Invasive adenocarcinoma of the breast stages I-III

        Exclusion Criteria:

          1. Other cancer diagnosis within the last 5 years

          2. Other physical problems that can affect survival

          3. Other physical problems that can affect sleep or mood ex) pulmonary disease(COPD,
             Asthma), GI disorder(GERD), Renal disorder(End stage renal disease), Endocrine
             disorder(Hypothyroidism, Acromegaly), Infectious disease(Viral, bacterial infections,
             HIV infections), Neurological disease(epilepsy, parkinson's disease, neuromuscular
             disorder, stroke, multiple sclerosis), Cardiovascular disease(Coronary heart disease),
             Pain, etc.

          4. ECOG(Eastern Cooperative Oncology Group performance status) &gt;1

          5. In the case of depression, anxiety disorder, sleep disorder, etc.

          6. If you have worked night shifts or shifts within the past 6 months

          7. Weight 40kg or less, digestive diseases, history of gastrointestinal surgery, etc.

          8. If you are currently taking psychiatric drugs (antipsychotics, antidepressant, mood
             stabilizer, benzodiazepine, psychostimulant, beta-blocker, etc.)

          9. If you have traveled on a transmeridian plane in the 3rd zone or more within the past
             6 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bong-Jin Hahm, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang-Hyup Jung, M.D.</last_name>
    <phone>82220723767</phone>
    <email>jshyup@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>140-013</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Hyup Jung, M.D.</last_name>
      <phone>82220723767</phone>
      <email>jshyup@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.snuh.org/</url>
    <description>study site webpage</description>
  </link>
  <link>
    <url>https://cris.snuh.org/ncris/</url>
    <description>Institutional Review Board</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast neoplasms</keyword>
  <keyword>Circadian rhythm</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Core body temperature</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Cortisol</keyword>
  <keyword>Circadian gene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

